FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
Another analyst is on the Keryx Biopharmaceuticals (NASDAQ: KERX) 'going to $15' bandwagon following positive Phase 3 data.
In addition to Roth Capital... More

